RxDoctor Payments Data

Glenn Gangi, MD

Urology · Mullins, SCNPI 1932176195

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 44 manufacturers reported payments, led by Coloplast at 24.0% of the total.

$12,007in general payments, 2019–2025

Across 321 payments — averaging $37.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$3K
  • Boston Scientific$2K
  • Teleflex LLC$959
  • Neotract Inc.$829
  • AbbVie$717
  • Endo Pharmaceuticals Inc.$677
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$2142%
  • Food & beverage$11,76998%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,007 in reported general payments places this provider in the 80th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$862,843
Medicare patients
2,218
Services billed
19,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron111$107,586
MyrbetriqMirabegron113$91,142
Abiraterone Acetate12$54,314
Tamsulosin Hcl2,283$39,445
Solifenacin Succinate770$36,873
Finasteride1,816$26,964
Estradiol375$22,303
Alfuzosin Hcl ErAlfuzosin Hcl400$10,634
Ciprofloxacin Hcl1,373$6,061
Potassium Citrate ErPotassium Citrate74$4,974
Dutasteride97$4,417
Testosterone52$4,344
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,125$3,579
Oxybutynin Chloride143$3,130
Tolterodine Tartrate ErTolterodine Tartrate41$3,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$342$107,586111 claims
Astellas Pharma US IncMyrbetriq$48$91,142113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 196 urology providers in South Carolina.

Other urology in Mullins

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →